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Abstract
Metabotropic glutamate (mGlu) receptors have been considered potential targets for the therapy of experimental
parkinsonism. One hypothetical advantage associated with the use of mGlu receptor ligands is the lack of the adverse
effects typically induced by ionotropic glutamate receptor antagonists, such as sedation, ataxia, and severe learning
impairment. Low doses of the mGlu2/3 metabotropic glutamate receptor agonist, LY379268 (0.25–3 mg/kg, i.p.) increased
glial cell line-derived neurotrophic factor (GDNF) mRNA and protein levels in the mouse brain, as assessed by in situ
hybridization, real-time PCR, immunoblotting, and immunohistochemistry. This increase was prominent in the striatum, but
was also observed in the cerebral cortex. GDNF mRNA levels peaked at 3 h and declined afterwards, whereas GDNF protein
levels progressively increased from 24 to 72 h following LY379268 injection. The action of LY379268 was abrogated by the
mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.), and was lost in mGlu3 receptor knockout mice, but not in mGlu2
receptor knockout mice. In pure cultures of striatal neurons, the increase in GDNF induced by LY379268 required the
activation of the mitogen-activated protein kinase and phosphatidylinositol-3-kinase pathways, as shown by the use of
specific inhibitors of the two pathways. Both in vivo and in vitro studies led to the conclusion that neurons were the only
source of GDNF in response to mGlu3 receptor activation. Remarkably, acute or repeated injections of LY379268 at doses
that enhanced striatal GDNF levels (0.25 or 3 mg/kg, i.p.) were highly protective against nigro-striatal damage induced by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice, as assessed by stereological counting of tyrosine hydroxylase-positive
neurons in the pars compacta of the substantia nigra. We speculate that selective mGlu3 receptor agonists or enhancers are
potential candidates as neuroprotective agents in Parkinson’s disease, and their use might circumvent the limitations
associated with the administration of exogenous GDNF.
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Introduction
Metabotropic glutamate (mGlu) receptors have been considered
potential targets for neuroprotective drugs since the early times of
their characterization. One hypothetical advantage associated with
the use of mGlu receptor ligands is the lack of the adverse effects
typically induced by N-metyl-D-aspartate (NMDA) or a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor antag-
onists, such as sedation, ataxia, and severe learning impairment
[1,2]. mGlu receptors form a family of eight subtypes (mGlu1 to
28), subdivided into three groups on the basis of their amino acid
sequence, pharmacological profile and transduction pathways.
Group-II mGlu receptors (including subtypes mGlu2 and mGlu3)
are best candidates as ‘‘neuroprotective receptors’’ because their
activation inhibits glutamate release [3,4,5,6,], inhibits voltage-
gated calcium channels [7], positively modulates potassium
channels [8], and stimulates the production of neurotrophic
factors in astrocytes and microglia [9,10,11,12,13]. The use of
mixed cell cultures containing both neurons and astrocytes has
shown that activation of glial mGlu3 receptors enhances the
formation of transforming-growth factor-b (TGF-b), which in turn
protects neighbor neurons against excitotoxic death [9,10,12,14,].
This raises the intriguing possibility that pharmacological
activation of particular mGlu receptor subtypes may slow the
progression of neurodegenerative disorders through a non
conventional mechanism based on the production of endogenous
neurotrophic factor. A recent review highlights the potential role
of mGlu receptors in the experimental treatment of Parkinson’s
disease [15], in which only symptomatic drugs are currently used.
A particular advantage of subtype-selective mGlu receptor ligands
(such as mGlu2/3 receptor agonists, mGlu4 receptor enhancers,
or mGlu5 receptor antagonists) is that these drugs not only relieve
motor symptoms, but are also protective against nigro-striatal
damage at least in experimental animal models of parkinsonism
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6591[13,16,17,18,19,20,21]. Along this line, we decided to study
whether activation of group-II mGlu receptors influences the
endogenous production of glial cell line-derived neurotrophic
factor (GDNF), which is a potent factor for survival and axonal
growth of mesencephalic dopaminergic neurons and has been
shown to improve motor symptoms and attenuate nigro-striatal
damage in experimental animal models of parkinsonism
[22,23,24,25,26]. Several clinical trial have evaluated the efficacy
of intraputaminal infusion of GDNF in Parkinsonian patients with
contrasting results (see Discussion and references therein).
Interestingly, the protective activity of GDNF in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of parkinsonism
requires the presence of TGF-b [27], suggesting that strategies
aimed at enhancing the endogenous production of both GDNF
and TGF-b may be particularly successful in slowing the
progression of Parkinson’s disease.
We now report that selective pharmacological activation of
mGlu3 receptors enhances the production of GDNF in mouse
striatum, and that the potent mGlu2/3 receptor agonist,
LY379268, is highly protective in the MPTP model of parkinson-
ism at doses that up-regulate GDNF.
Results
1. Pharmacological activation of mGlu3 receptors
enhances GDNF formation in the striatum
Mice were systemically injected with LY379268, a drug that
selectively activates mGlu2/3 receptors with nanomolar potency
and is systemically active [28]. In situ hybridization analysis showed
that LY379268 treatment increased GDNF mRNA levels in the
striatum (Fig. 1A), but had no effect on NGF mRNA (Fig. 1B).
LY379268 treatment increased the amount of GDNF mRNA,
evaluated as number of grains per cell (saline=25.9661.1 vs
LY379268=32.3560.71, p,0.002) without affecting the number
of GDNF-mRNA positive cells (not shown). Dose-dependent
experiments showed an inverse-U shaped dose-response curve,
with maximal responses at 0.25 mg/kg of LY37968, a plateau
between 0.25 and 3 mg/kg, and loss of response at 4 mg/kg, i.p.
(Fig. 1C). This is remarkable because LY379268 is usually
administered to mice at systemic doses.0.3–0.5 mg/kg
[18,29,30,31,32,33]. The increase in striatal GDNF mRNA levels
induced by a single injection of LY379268 peaked after 3 h
(Fig. 1D) and was prevented by the preferential mGlu2/3 receptor
antagonist, LY341495 (1 mg/kg, i.p.), which had no effect on its
own (Fig. 1E). Quantitative analysis by real-time PCR confirmed
the increase in GDNF mRNA induced by LY379268 at 3 h and
showed a residual effect at 6 h that was not detected by in situ
hybridisation analysis (Fig. 2A). In addition, real-time PCR
analysis revealed an effect of LY379268 on GDNF mRNA levels
in the cerebral cortex, which, however, was only detected at 6 h
(note that GDNF levels are 10-fold lower in the cerebral cortex
than in the striatum) (Fig. 2B). We extended the study to GDNF
protein levels, which we measured by immunoblotting in striatal
and cortical extracts from mice treated with LY379268.
Treatment with 0.25 mg/kg LY379268 increased GDNF protein
levels in both the striatum and cerebral cortex after 72 h
(Fig. 3A,B). When mice were treated with 3 mg/kg LY379268,
GDNF levels increased in the striatum after 24 h and returned
back to normal at 72 h (Fig. 3C). All these effects were prevented
by the antagonist, LY341495 (Fig. 3A–C). Interestingly, the high
dose of LY379268 had no effect on GDNF levels in the cerebral
cortex (Fig. 3D). To unravel the identity of the mGlu receptor
subtype that mediates the increase in GDNF levels, we
administered LY379268 (3 mg/kg, i.p.) to mice lacking either
mGlu2 or mGlu3 receptors, and examined GNDF levels in the
striatum 24 h later. Basal GDNF levels did not differ among wild-
type, mGlu2
2/2 and mGlu3
2/2 mice (Fig. 4A). In contrast,
treatment with LY379268 was able to enhance GDNF levels in
wild-type and mGlu2
2/2 mice, but not in mGlu3
2/2 mice (Fig. 4B).
2. The increase in GDNF mediated by mGlu3 receptors
selectively occurs in neurons
A combination of in vivo and in vitro experiments clearly showed
that the source of the GDNF responsive to mGlu3 receptor
activation was exclusively neuronal. Double labelling analysis by
combined in situ hybridization and immunohistochemistry (GDNF
mRNA+NeuN or GFAP) showed that GDNF is expressed in
neurons (Fig. 5A) and treatment with LY379268 (0.25 mg/kg, i.p.,
3 h) selectively increased GDNF mRNA levels in neurons (not
shown). GDNF immunostaining was also performed in the
striatum of mice treated 7 days before with high doses of the
parkinsonian toxin, MPTP (20 mg/kg, i.p., x 3, two h apart). This
treatment led to reactive gliosis in the striatum, as a result of the
degeneration of nigro-striatal dopaminergic neurons (see GFAP
immunostaining in Fig. 5C). Under these conditions, GDNF
immunostaining was localized both in neurons and reactive
astrocytes. A single injection of LY379268 (3 mg/kg, i.p.) 7 days
following MPTP injection did not enhance GDNF immunoreac-
tivity in reactive astrocytes, but still enhanced immunoreactivity in
neurons. Interestingly, the number of GDNF
+ reactive astrocytes
was even less 24 h following LY379268 injection (Fig. 5B).
3. Activation of mGlu3 receptors enhances GDNF levels in
cultured striatal neurons (but not in astrocytes) via the
activation of the MAP kinase and the
phosphatidylinositol-3-kinase pathways
In in vitro studies, basal GDNF levels were about 3 fold higher in
cultured mouse striatal neurons than in cultured astrocytes
(Fig. 6A). Treatment of cultured neurons with 1 mM LY379268
enhanced GDNF levels 24 h later. This effect was abrogated by a
co-application of the MEK inhibitor, PD98059 (30 mM), or the
phosphatidyilinositol-3-kinase (PI-3-K) inhibitor, LY294002
(30 mM) (Fig. 6C). As expected, LY379268 activated both the
MAP kinase and the PI-3-K pathways, as shown by an increased
levels of phosphorylated ERK1/2 and phosphorylated Akt,
respectively. The action of LY379268 was abrogated by the
antagonist, LY341495 (1 mM) (Fig. 6B). Application of LY379268
to quiescent astrocytes (not shown) or astrocytes made ‘‘reactive’’
by several passages in culture and by the G5 supplement in the
medium did not affect GDNF levels (Fig. 6D).
4. Doses of LY379268 that are effective in enhancing
GDNF levels protect nigro-striatal neurons against MPTP
toxicity in mice
We decided to examine whether doses of 0.25 or 3 mg/kg of
LY379268, which enhanced GDNF levels in the striatum, were
protective against nigro-striatal damage in mice treated with
MPTP. We used a dose of MPTP (30 mg/kg, single i.p. injection)
that causes about a 40–50% degeneration of nigro-striatal
dopaminergic neurons, and is known to be insensitive to higher
doses of LY379268 (5 or 10 mg/kg, i.p.) [18]. The number of
nigral neurons was assessed by stereological counting 7 days
following MPTP injection. Mice receiving either 0.25 or 3 mg/kg
LY379268 30 min prior to MPTP injection or mice receiving
0.25 mg/kg LY379268 once a day for 7 days starting from the day
of MPTP injection were significantly protected against nigro-
striatal damage. In mice treated with MPTP alone there was a loss
mGlu3 Receptors and GDNF
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nigra. The number of surviving neurons substantially increase in
mice receiving either a single or a repeated injection with
0.25 mg/kg LY379268, and returned back to normal in mice
receiving a single injection with 3 mg/kg LY379268 (Fig. 7).
Searching for a correlation between GDNF and neuroprotection,
we measured GDNF levels in response to the most effective dose of
LY379268 (3 mg/kg, single injection) given alone or in combina-
tion with MPTP. In control mice, striatal GDNF levels were
approximately 55–65 pg/mg protein, and were relatively stable at
1, 2, 3, and 7 days after the injection of saline. A single injection of
LY379268 alone enhanced GDNF levels by more than 2 fold after
1 day. The increase was still visible at 2 days and became
negligible at 3 and 7 days. MPTP alone did not change GDNF
 
 
 
 
 
Figure 1. In situ hybridization of sagittal sections at basal ganglia level showing the expression of mRNA encoding GDNF (A) or NGF
(B). Autoradiogram showing GDNF expression in the striatum of saline-treated mice or LY379268 (0.25 mg/kg, i.p.)-treated mice (A). The inserts show
representative GDNF mRNA labeled cells (black grains) with increased levels of labeling in LY379268-treated mice. Autoradiogram showing NGF
expression of saline-treated mice or LY379268 (0.25 mg/kg, i.p.)-treated mice (B). Dose-response curve of GDNF mRNA levels in the striatum of mice
treated with saline or LY379268 (0.1, 0.25, 1, 3 or 4 mg/kg, i.p) (C) and time-course of GDNF mRNA levels in the striatum of mice after a single injection
of LY379268 (0.25 mg/kg, i.p.) (D); values are means6S.E.M (n=4–5, animals per group; three independent experiments). Striatal GDNF mRNA levels
in mice treated with saline, LY379268 (0.25 mg/kg, i.p), LY341495 (1 mg/kg, i.p) or LY379268+LY341495 (E); value are means6S.E.M (n=4, animals per
group; three independent experiments). *p,0.05; **p,0.01 (One-way ANOVA+Fisher’s PLSD) vs. control mice. Scale bar: A–B=4 mm. Str, striatum;
Ctx, cortex; Hipp, hippocampus.
doi:10.1371/journal.pone.0006591.g001
mGlu3 Receptors and GDNF
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perhaps as a result of reactive gliosis (see above). Interestingly, the
combination of LY379268 further enhanced the increase in
GDNF levels induced by MPTP at 2 and 3 days (Fig. 8). To
examine the causal relationship between the increase in GDNF
levels and neuroprotection, we used mice unilaterally implanted
with gelfoam (Spongostan) pre-adsorbed with saline alone
(controls) or with saline containing 5 mg of neutralizing anti-
GDNF antibodies into the left caudate nucleus. In control mice,
systemic injection of LY379268 (3 mg/kg, i.p.) protected nigro-
striatal neurons against MPTP toxicity, as expected (Fig. 9A, B). In
mice implanted with Spongostan containing anti-GDNF antibod-
ies, MPTP caused a greater loss of TH-positive nigral neurons in
the implantation side (left side). Interestingly, treatment with
LY379268 was still protective against MPTP toxicity in the side
contralateral to implantation (right side), but lost its protective
activity in the implantation side (Fig. 9A, B).
Discussion
The evidence that the mGlu2/3 receptor agonist, LY404039,
relieves psychotic symptoms in schizophrenic patients [34] has
renewed the interest on group-II mGlu receptors. However, it is
the mGlu2 receptor that mediates the antipsychotic activity of
mGlu2/3 receptor agonists [33,35,36], while the mGlu3 receptor
is still in search of a function that can be relevant for human
studies. Using mixed cultures of mouse cortical cells, we have
found that the protective activity of LY379268 against excitotoxic
neuronal death is entirely mediated by the mGlu3 receptor [14].
Activation of mGlu3 receptors present in astrocytes enhances the
production of TGF-b, which in turn protects neighbour neurons
against excitotoxicity [10,12]. Activation of mGlu3 receptors can
also enhance the production of nerve growth factor (NGF) and S-
100b in cultured astrocytes [11], and group-II mGlu receptor
agonists stimulate the secretion of brain-derived neurotrophic
factor from cultured microglia [13,16]. It seems therefore that the
mGlu3 receptor is endowed with the unusual activity of regulating
the production of neurotrophic factors in glial cells. We have now
extended this function to neurons, where activation of mGlu3
receptors stimulated GDNF production. This particular activity
was prominent in striatal neurons, which are a major source of
GDNF in the forebrain [37,38]. Interestingly, the orthosteric
mGlu2/3 receptor agonist, LY379268, displayed an unusually
high potency in stimulating GDNF production in the striatum of
living mice, with doses as low as 0.25 mg/kg, displaying maximal
activity, and doses$4 mg/kg being inactive. There are a number
of potential explanations for the lack of activity of high doses of
LY39268, which include the recruitment of additional mGlu
receptor subtypes, such as mGlu2 and mGlu8 receptors [39], the
recruitment of additional intracellular pathways that negatively
regulate the transcriptional machinery of the GDNF gene, or the
development of tachyphylaxis. Using pure cultures of striatal
neurons we could establish that activation of mGlu3 receptors
enhanced GDNF production by stimulating the MAPK and the
PI-3-K pathways. This was expected because the MAPK and PI-
3-K pathways mediate the effect of mGlu3 receptor activation on
TGF-b production in cultured astrocytes [12]. Perhaps it is not a
mere coincidence that the same receptor positively regulates the
formation of GDNF and TGF-b. GDNF and other GDNF-family
ligands, such as neurturin, artemin, and persephin, belong to the
TGF-b superfamily and share with TGF-b the protein conforma-
tion and the ability to function as homodimers [40]. Interestingly,
GDNF and TGF-b act synergistically as neuroprotectants
although the respective receptors do not share the same
transduction machinery. For example, endogenous TGF-b is
required for the ability of GDNF to rescue target-derived
Figure 2. Quantitative real-time PCR analysis of GDNF mRNA in mouse striatum (A) and cortex (B) at 3, 6 or 12 h after systemic
treatment with saline, LY379268 (3 mg/kg, i.p.), or LY379268 (3 mg/kg, i.p.)+LY341495 (1 mg/kg, i.p.). Values were normalized with
respect to the amount of b-actin mRNA. Values are mean+S.E.M. of four determinations (each from triplicates). *p,0.05 (One-way ANOVA+Fisher’s
PLSD) vs. saline-treated mice.
doi:10.1371/journal.pone.0006591.g002
mGlu3 Receptors and GDNF
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Figure 3. Western blot analysis of GDNF expression in the striatum (A,C) or cerebral cortex (B,D) of mice after treatment with saline,
LY379268, 0.25 (A,B) or 3 (C,D) mg/kg, i.p., or LY379268+LY341495, 1 mg/kg, i.p. Animals were killed 24 or 72 h after treatments.
Densitometric data of GDNF are shown and are the mean+S.E.M. of 3 animals performed two times.*p,0.05 (One-way ANOVA+Fisher’s PLSD) vs.
saline-treated mice.
doi:10.1371/journal.pone.0006591.g003
mGlu3 Receptors and GDNF
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the three isoforms of TGF-b abolish the protective activity of
GDNF against MPTP-induced nigro-striatal lesions in mice [27].
Although the molecular nature of the cross-talk between GDNF
and TGF-b is unknown, drugs that enhance the production of
both factors are promising candidates as neuroprotective agents.
GDNF was shown to behave as a potent neurotrophic factor for
midbrain dopaminergic neurons since the time of its discovery
[22]. Interestingly, TGF-b also behaves as a survival factor for
midbrain dopaminergic neurons [42]. Moving from the consistent
neuroprotective and restoring activity in experimental models of
parkinsonism (see references in Introduction), GDNF has been
evaluated in several clinical trials for its effect on Parkinson’s
disease. Intracerebroventricular injection of GDNF was inactive
[43], whereas direct intraputaminal infusion of GDNF produced
beneficial effects in two phase-I clinical trials [44,45], but was not
successful in another double-blinded placebo controlled study
[46]. The use of brain-permeant drugs that mimic the action of
GDNF or enhance the production of endogenous GDNF is an
attractive strategy that may overcome the limitations associated
with an invasive delivery of GDNF into the brain. For example,
the orally active compound, PYM50028, which elevates striatal
levels of GDNF, is protective against MPTP toxicity in mice [47],
and induction of GDNF is associated with the neurorescue action
of rasagilin, a drug of current use in the treatment of Parkinson’s
disease [48,49]. Brain-permeant mGlu2/3 receptor agonists are
particularly promising for the experimental treatment of Parkin-
son’s disease for the ability to enhance striatal levels of GDNF
(present data) and TGF-b [12,14]. The ability of GDNF-enhancing
doses of LY379268 to protect nigro-striatal neurons against MPTP
toxicity supports the use of mGlu2/3 receptor agonists as
neuroprotectants in Parkinson’s disease. An important question is
whether the amount of GDNF produced in response to LY379268
was sufficient to afford neuroprotection against MPTP toxicity. In
control mice, striatal GDNF levels were about 60 pg/mg prot., a
value similar to that reported in [47]. A single injection of
LY379268 increased striatal GDNF levels by about 80–100 pg/
mg protein after 48–72 hours. These are steady-state levels that
reflect the equilibrium between production and clearance/degra-
dation of GDNF, and do not discriminate between intracellular and
extracellular GDNF. A direct demonstration that these steady-state
levels of GDNF are neuroprotective requires accurate titration
experiments with viral vectors, and is technically difficult. However,
it is remarkable that neuroprotective doses of compound
PYM50028, which is in clinical development for the treatment of
Parkinson’s disease, induce increases in striatal GDNF levels in
MPTP-treated mice similar to those induced by LY379268 in our
study [47]. We were unable to use mutant mice lacking GDNF to
examine the direct link between GDNF and the protective activity
of LY379268 against MPTP toxicity. Thus, we adopted an
alternative strategy based on the implantation of neutralizing anti-
GDNF antibodies in the caudate nucleus. We adopted the same
experimental protocol developed in [27], based on the unilateral
implantation of a gelfoam adsorbed with the antibody. The loss of
nigral neurons in response to MPTP was slightly greater in the
implantation side, suggesting that endogenous production of GDNF
Figure 4. Western blot analysis of striatal GDNF expression in wild-type, mGlu2
2/2 or mGlu3
2/2 mice in basal conditions (A) and
after treatment with LY379268, 3 mg/kg, i.p. (B). Animals were killed 24 h later. Densitometric data of GDNF are shown and are the
mean+S.E.M. of 3 animals performed two times.*p,0.05 (One-way ANOVA+Fisher’s PLSD) vs. saline-treated mice.
doi:10.1371/journal.pone.0006591.g004
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PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6591Figure 5. Double immunolabeling for GDNF and NeuN or GFAP in striatal cells showing the labelling of GDNF within neuronal cells
(A). Arrows in the left panel, NeuN-positive cells containing GDNF mRNA black grains; arrow in the right panel, GDNF mRNA black grains, arrow head
in the right panel, GFAP-positive cell. Immunohistochemical analysis of GDNF in the striatum of mice treated with a single injection of LY379268
(3 mg/kg, i.p.) and killed 24 h later (B). In both control mice and mice treated with LY379268, GDNF immunoreactivity is exclusively localized in
neurons (note the absence of co-localization between GDNF and GFAP), and the extent of immunostaining increases after drug treatment. GDNF
immunostaining in the striatum of mice treated 7 days before with MPTP, 20 mg/kg, i.p., x 3, two h apart (C). This treatment led to reactive gliosis in
the striatum, as a result of the degeneration of nigro-striatal dopaminergic neurons. Under these conditions, GDNF immunostaining is localized both
in neurons and reactive astrocytes. A single injection of LY379268 (3 mg/kg, i.p.) 7 days following MPTP injection did not enhance GDNF
immunoreactivity in reactive astrocytes, but still enhanced immunoreactivity in neurons. Interestingly, the number of GDNF-positive reactive
astrocytes is lower 24 h following LY379268 injection. Scale bar=50 and 10 mm.
doi:10.1371/journal.pone.0006591.g005
mGlu3 Receptors and GDNF
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protective activity in the implantation side, lending credit to the
hypothesisthat mGlu3 receptoractivation protectsviaan increase in
striatal GDNF levels. The presence of the anti-GDNF antibodies
was the critical determinant in these experiments because
LY379268 was still protective when a gelfoam lacking the antibody
was implanted in the striatum.
In conclusion, we have shown that activation of mGlu3
r e c e p t o r se n h a n c e sG D N Fl e v e l si nn e u r o n s ,a n dt h a td o s e so fa
mGlu2/3 receptor agonist that enhance GDNF levels in the
striatum are protective against MPTP-induced nigro-striatal
damage. This finding is particularly interesting because phar-
macological activation of mGlu2/3 receptors can also improve
motor deficits in experimental models of parkinsonism [50,51].
The good profile of safety and tolerability of mGlu2/3 receptor
agonists in clinical studies [34] may encourage the use of mGlu2/
3 receptor agonists in the experimental treatment of Parkinson’s
disease.
Figure 6. Basal GDNF levels in cultured mouse striatal neurons and in cultured astrocytes (A). Expression of phosphoERK1/2 and
phospho-Akt in cultured striatal neurons treated with LY379268 (1 mM), LY341495 (1 mM) and LY379268+LY341495 for 15 min (B). Densitometric
values are means+S.E.M. of 3–4 determinations. *p,0.05 (One-Way ANOVA+Fisher’s PLSD) vs. basal values, #p,0.05 vs. LY379268 values. Treatment
of cultured neurons with 1 mM LY379268 enhanced GDNF levels 24 h later (C), and it was abrogated by the co-application of the MEK inhibitor,
PD98059, or the PI-3-K inhibitor, LY294002 (C). Application of LY379268 to astrocytes made ‘‘reactive’’ by several passages in culture and by the G5
supplement in the medium did not affect GDNF levels (D).
doi:10.1371/journal.pone.0006591.g006
mGlu3 Receptors and GDNF
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(-)-2-Oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylic acid
(LY379268) was kindly provided by Eli Lilly Research Laborato-
ries (Indianapolis, IN). (2S)-2-Amino-2-[(1S,2S)-2-carboxycyclo-
prop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495) was pur-
chased from Tocris Cookson Ltd. (Bristol, UK). All other
chemicals were purchased from Sigma (Milano, Italy).
mGlu2 and mGlu3 receptor knockout mice
mGlu2 receptor knockout mice (mGlu2
2/2) were obtained from
University of Kyoto, Japan [52]. mGlu3 receptor knockout mice
(mGlu3
2/2) were generated by GlaxoSmithKline, Verona, Italy
[14]. Mice were backcrossed up to the 17th generation on
C57BL/6J genetic background and bred in a specific pathogen-
free (SPF) breeding colony.
Preparation of mouse striatal cultures
Glial cell cultures were prepared from striatum of postnatal C57
Black mice (1–3 days after birth), as previously described [53].
Dissociated striatal cells were grown in 100 mm dishes (Falcon
Primaria, Lincoln Park, NJ) using a plating medium of MEM-
Eagle’s salts supplemented with 10% of heat inactivated horse
serum, 10% fetal bovine serum, 2 mM glutamine, 25 mM sodium
bicarbonate and 21 mM glucose. Cultures were kept at 37uCi na
humidified CO2 atmosphere. After confluence had been reached,
the cells in each dish were dissociated by trypsin treatment and
plated in new dishes. In one set of experiments cell differentiation
was initiated by decreasing the foetal bovine serum concentration
to 3% and the culture medium was also supplemented for 10 days
with the defined culture additive G5 medium diluted 1/100, as
suggested by the manufacturer (composition: insulin 500 mg/ml,
human transferrin 5000 mg/ml, selenite 0.52 mg/ml, biotin
1 mg/ml, hydrocortisone 0.36 mg/ml, FGF2 0.52 mg/ml and
EGF 1 mg/ml) in order to trigger astrocyte activation. After
confluence had been reached, the cells were then incubated with
LY379268 (1 mM) for 24 h. The control culture received the same
volume of MEM. Cells were collected after incubation and stored
at 280uC until use. In another set of experiments secondary
astrocytes were exposed for about 1 week to FCS-free MEM
     
Figure 7. Immunohistochemical analysis of TH in the pars compacta of substantia nigra of mice injected with a single i.p. dose
of 30 mg/kg of MPTP, alone or combined with LY379268 (0.25 or 3 mg/kg in a single i.p. injection, 30 min prior to MPTP
injection or 0.25 mg/kg/7 days once a day, i.p.). Scale bar=100 mm. Stereological TH-positive cell counts are also shown. Values
(means+S.E.M.) were calculated from 7–8 mice per group (10 sections - 10 mm thick, cut every 100 mm, per animal were used for the calculation
of the density of TH-positive neurons in the pars compacta of the substantia nigra). *p,0.05 (One-way ANOVA+Fisher’s PLSD) vs. mice treated
with MPTP alone.
doi:10.1371/journal.pone.0006591.g007
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cells were incubated with LY379268 (1 mM) for 0–24 h.
Pure neuronal cultures were prepared from striatum of E14-16
C57 Black mice, as previously described [53]. Dissociated striatal
cells were grown in 100 mm dishes (Falcon Primaria, Lincoln Park,
NJ) using the Neurobasal plating medium supplemented with B27.
Cultures were kept at 37uC in a humidified CO2 atmosphere and
used at 13 DIV. Pure neuronal cultures were incubated with
LY379268 (1 mM) for 24 h in the presence or absence of the MEK
inhibitor, PD98059 (30 mM), or the PI-3-K inhibitor, LY294002
(30 mM) or the group II antagonist, LY341495 (1 mM). Cells were
collected after incubation and stored at 280uC until use.
     
Figure 8. ELISA analysis of GDNF expression in the striatum of mice after treatment with saline, LY379268 (3 mg/kg, i.p.), MPTP
(30 mg/kg, i.p.), or MPTP+LY379268. Animals were killed 1,2,3 or 7 days after treatments. Data of GDNF are the mean+S.E.M. of 8 animals.
p,0.05 (One-way ANOVA+Fisher’s PLSD) vs. the corresponding groups of mice treated with saline (*) or with MPTP or LY379268 alone (#).
doi:10.1371/journal.pone.0006591.g008
 
 
Figure 9. LY379268 fails to protects against MPTP toxicity in mice unilaterally implanted with anti-GDNF antibodies. Mice were
implanted with a gelfoam (Spongostan) pre-soaked with saline alone (A,B) or a saline solution containing 5 mg of neutralizing anti-GDNF antibodies
(A,B) in the left caudate nucleus. Stereological counts of TH-positive neurons in the substantia nigra pars compact in the implantation side (left) or
contralateral side (right) in response to i.p. injection of saline, LY379268 (3 mg/kg), MPTP alone (30 mg/kg) or MPTP+LY379268 (injected 30 min prior
to MPTP injection). Drugs were administered 24 h after the gelfoam implantation. Mice were killed 7 days after MPTP injection. Values (means+S.E.M.)
were calculated from 6 mice per group. p,0.05 (One-way ANOVA+Fisher’s PLSD) vs. the corresponding values in mice treated with saline (*) or vs. the
MPTP values of the right side (#).
doi:10.1371/journal.pone.0006591.g009
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Adult male C57 Black mice (22–24 g b.w., Charles River,
Calco, Verona, Italy) were housed with a 12-h light-dark cycle and
food and water ad libitum. All animal experimental procedures
were carried out in accordance with the directives of the Italian
and European Union regulations for the care and use of
experimental animals and were approved by the Italian Ministry
of Health.
Groups of 4–5 mice were treated with saline, LY379268 (0.1–
3 mg/kg, i.p.) or LY379268+LY341495, the preferential mGlu2/3
receptor antagonist (1 mg/kg, i.p.) to study the expression of
GDNF mRNA levels by in situ hybridization. A time-course study
on GDNF mRNA expression was also performed using LY379268
(0.25 mg/kg, i.p.). Animals were sacrificed at 0, 2, 3 and 6 h under
deep anesthesia and brains were rapidly frozen in cooled
isopentane and stored at 280uC until used. Other groups of 6–8
animals were injected systemically with either saline, LY379268
(0.25–3 mg/kg, i.p.) or LY379268+LY341495 (1 mg/kg, i.p.), and
killed at different times after a single injection. In particular,
animals were sacrificed at 3, 6, 12, 24, and 72 h by cervical
dislocation. Brains were rapidly removed and cortex and striatum
were dissected out and immediately frozen on dry ice and stored at
280uC until used. These animals were utilized for the detection of
GDNF mRNA by real-time RT-PCR analysis and GDNF protein
levels by Western blot analysis.
Wild-type, mGlu2
2/2 and mGlu3
2/2 mice were treated with
saline or LY379268 (3 mg/kg, i.p.) and killed 24 h later. Both
striata were dissected out and immediately homogenized in RIPA
buffer for mesurements of GDNF protein levels. The amount of
GDNF protein was assessed by Western blot analysis.
Groups of 6 C57 Black mice were treated with three i.p.
injections, two h apart, of 24 mg/kg of MPTP (corresponding to
20 mg/kg of free MPTP). Seven days later mice were systemically
injected with LY379268, 3 mg/kg, i.p., and killed 24 h later.
These mice were used for immunohistochemical analysis of striatal
GDNF and glial fibrillary acidic protein (GFAP). Additional group
of 8 C57 Black mice were also treated with a single i.p. injection of
36 mg/kg of MPTP (corresponding to 30 mg/kg of free MPTP)
and treated with a single i.p. injection of LY379268, 0.25 or 3 mg/
kg, 30 min prior to MPTP injecton or injected i.p. daily with
LY379268, 0.25 mg/kg. These mice were killed 7 days after
MPTP injection and used for assessment of nigro-striatal damage
by stereological cell counting of nigral tyrosine hydroxylase (TH)-
positive cells. Additional groups of 8 C57 Black mice were treated
with a single i.p. injection of 36 mg/kg of MPTP (corresponding
to 30 mg/kg of free MPTP) or treated with a single i.p. injection of
LY379268, 3 mg/kg, 30 min prior to MPTP injection. Control
groups were treated with saline or LY379268, 3 mg/kg, i.p. These
mice were killed 1, 2, 3 or 7 days after MPTP injection and used
for measurements of GDNF levels in the striatum by ELISA.
Additional groups of 6 C57 Black mice were unilaterally
implanted in the left caudate nucleus with pieces of gelfoam
(Spongostan, Johnson & Johnson Medical, Milano, Italy,
1.561.561.5 mm in size) soaked in 5 ml of saline alone (controls)
or in 5 ml of saline containing neutralizing anti-GDNF antibody
(R&D Systems; 5 mg/gelfoam). The gelfoam was placed in the
dorsal striatum underneath the corpus callosum (2.2–3.2 mm
depth) under anesthesia with ketamine (100 mg/kg)+xylazine
(10 mg/kg), i. p., in a Kopf stereotaxic frame (coordinates:
0.6 mm posterior to the bregma, 1.7 mm lateral to the midline,
2.2 mm ventral from the surface of skull, according to the atlas of
Franklin and Paxinos [54]. Twenty-four h later animals were
treated with saline or LY379268 (3 mg/kg, i.p.) followed, 30 min
later, by a saline injection or a single injection of 36 mg/kg of
MPTP (corresponding to 30 mg/kg of free MPTP). Mice were
killed 7 days after MPTP injection and used for assessment of
nigro-striatal damage by stereological cell counting of nigral TH-
positive cells (see below).
GDNF and NGF probe labelling and in situ hybridization
The GDNF cRNA probe was prepared from a fragment
containing 422-bp encompassing nucleotides 279–700 of the
originally published GDNF sequence, and cDNA subcloned into
the pcDNA3 (Stratagene, San Diego, CA, USA) [55]. The plasmid
was linearized with HindIII and used as a template for SP6 RNA
polymerase to generate the antisense probe or was linearized with
BstxI and transcribed with T7 RNA polymerase to generate the
sense probe. The NGF cRNA probe was prepared from a
fragment containing 777-bp of the NGF rat sequence, and cDNA
subcloned into the pBSKS (Stratagene, San Diego, CA, USA).
The plasmid was linearized with NcoI and used as a template for
T3 RNA polymerase to generate the antisense probe or was
linearized with EcoRII and transcribed with T7 RNA polymerase
to generate the sense probe.
Serial sagittal (lateral 1.70–1.00 mm) or coronal (A 4.70 mm–
5.70 mm) cryostat sections (14 mm) of mouse brain were prepared
at striatum level according to the atlas of Lehmann [56]. The in situ
hybridization procedure was used to examine the expression of
GDNF mRNAs in the striatum. Tissue sections were processed for
in situ hybridization as previously described [57]. Following fixation
in 4% paraformaldehyde for 15 min, slides were rinsed twice in
phosphate-buffered saline (PBS) and once in distilled water. Tissue
was deproteinated in 0.2 M HCl for 10 min, acetylated with 0.25%
acetic anhydride in 0.1 M ethanolamine for 20 min, and dehy-
drated with increasing concentrations of ethanol. Slides were
incubated for 16 h in a humidified chamber at 52uC with
86105 cpm probe in 70 ml hybridization cocktail (50% formamide,
20 mM Tris-HCl pH 7.6, 1 mM EDTA pH 8.0, 0.3 M NaCl,
0.1 M dithiothreitol, 0.5 mg/ml yeast tRNA, 0.1 mg/ml poly-A-
RNA, 1x Denhardt’s solution, and 10% dextran sulfate), washed
twice in 1x SSC (1x SSC=150 mM NaCl, 15 mM sodium citrate,
pH 7.0) at 62uC for 15 min, and then in formamide:SSC (1:1) at
62uC for 30 min. After an additional wash in 1x SSC at 62uC,
single-stranded RNA was digested by RNAse treatment (10 mg/ml)
for 30 min at 37uC in 0.5 M NaCl, 20 mM Tris-HCl pH 7.5,
2 mM EDTA. Slides were washed twice with 1x SSC at 62uC for
30 min before dehydration in ethanol and air-drying. For cell
localization of mRNA, hybridized sections were coated with NTB
Autoradiography Emulsion diluted in water (1:1) (Eastman-Kodak,
Rochester, NY, USA), and stored in desiccated light-tight boxes at
4uC for 4 weeks. Slides were developed with D19 (Eastman-Kodak),
fixed with Al-4 (Agfa Gevaert, Kista, Sweden), and counterstained
with Cresyl Violet. Semiquantitative data on GDNF mRNA levels
in the striatum were obtained by measuring the optical density of
the labelling of the autoradiogram films using Image J software
(Rasband, WS, ImageJ, U.S. National Institutes of Health,
Bethesda, MD, USA, http://rsb.info.nih.gov/ij, 1997–2002), and
by evaluation of silver grains over the individual cells from emulsion
dipped slides, using image analysis system (IAS-Counter, Delta-
Sistemi, Roma, Italy). No labeling was detected with sense
35S-
labeled riboprobes used as control of the hybridization specificity.
In situ hybridization and immunohistochemistry
We have used a combination of in situ hybridization and
immunohistochemical techniques to identify striatal cells expressing
GDNF mRNA. Brain cryostat sections were processed for in situ
hybridization and immunohistochemidtry. Immunohistochemistry
labelling was performed immediately after the last washing of the in
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incubated for 15 min in blocking buffer consisting of 2.5% normal
goat serum and 0.3% Triton X-100 in PBS. Subsequently, sections
were incubated overnight at 4uC in the presence of the primary
antibody diluted in PBS supplemented with 1.5% blocking serum.
Mouse monoclonal antibody (1:400, Sigma, St. Louis, MO), for the
detection of glial fibrillary acidic protein (GFAP) and anti-neuron
specific DNA-binding protein (NeuN, 1:400, Chemicon, Temecula,
CA, USA) were used as neuronal marker for immunohistochemistry.
Sections were then washed three times for 5 min in PBS, and
incubated at room temperature for 1 h with a biotinylated antimouse
antiserum (Amersham, U.K.), diluted 1:200. After three 5 min
washings with PBS, the sections were incubated for 1 h with a
horseradish peroxidase-streptavidin complex (Vector, Burlingame,
CA), diluted 1:100 in PBS. After on washing in PBS and one in Tris-
HCl buffer (0.1 M pH 7.4), the peroxidase reaction was developed in
the same buffer containing 0.05% 3,3-diaminobenzidine-4 HCl and
0.003% hydrogen peroxide. The reaction was stopped in Tris-HCl
buffer and after a short washing with H2O, the sections were
mounted onto 3-aminopropyl ethoxysilane coated slides dehydrated
in an ascending alcohol series, coated in NTB-2 emulsion (Kodak)
and processed as described above for autoradiographic development.
Analysis of GDNF expression by real-time quantitative
polymerase chain reaction (PCR)
Total RNA was extracted from mouse striatum and cortex using
Trizol reagent (Invitrogen, Milano, Italy) according to manufac-
turer’s instructions. Real-time quantitative PCR was performed
using a 2 x Supermix cocktail (Bio-Rad, Hercules, CA, USA)
containing the doublestranded DNA-binding fluorescent probe
Sybr Green and all necessary components except primers.
Quantitative PCR conditions included an initial denaturation step
of 94uC for 10 min followed by 40 cycles of 94uC for 15 s, and
55uC for 15 s. Standards, samples and negative controls (no
template) were analysed in triplicate. Concentrations of mRNA
were calculated from serially diluted standard curves simulta-
neously amplified with unknown samples and normalized with
respect to b-actin mRNA levels. The following primers were used:
GDNF, GCCACCATTAAAAGACTGAAAAGG (forward), GC-
CTGCCGATTCCTCTCTCT (reverse), b-actin, GGTCAT-
CACTATCGGCAAT (forward), GAATGTAGTTTCATGGA-
ATGC (reverse).
Western blot analysis of GDNF levels
Mouse striatum, cortex and cell cultures were homogenized at
4uC in a buffer composed of Tris-HCl pH 7.4, 10 mM; NaCl,
150 mM; EDTA, 5 mM; PMSF, 10 mM; Triton X-100, 1%;
leupeptin, 1 mg/ml; aprotinin, 1 mg/ml. Samples were centrifuged
at 12000 g for 10 min at 4uC. Equal amounts of proteins (30 mg)
from supernatants were separated by 12.5% SDS polyacrilamide
gel. After separation, proteins were transferred on immun-blot
PVDF membranes. Membranes were incubated overnight at 4uC
with a monoclonal anti-human GDNF antibody (1.5 mg/ml,
Chemicon International Inc., Temecula, CA) and then incubated
for 1 h with the secondary antibody (1:5000, peroxidase-coupled
anti-mouse, Amersham, Milano, Italy). Immunostaining was
revealed by the enhanced ECL western blotting analysis system
(Amersham, Milano, Italy). The blots were reprobed with anti-b-
actin monoclonal antibody (1:250, Sigma, St. Louis, MO).
GDNF quantification by ELISA
Mouse striatum was dissected and homogenized in 300 ml lysis
buffer at 4uC containing 137 mM NaCl, 20 mM Tris, 1%
Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonylflouride,
10 mg/ml aprotinin, 1 mg/ml leupeptin, and 0.5 mM sodium
orthovanadate and then centrifuged at 10,000 g for 10 min at 4uC.
The supernatants were removed for ELISA analysis of GDNF,
using a commercially available kit (Promega, Madison, WI, USA).
Protein content was assessed by the Bradford method. Briefly, 96-
well plates were coated with anti-GDNF monoclonal antibody
(Promega) overnight. Plates were then washed and nonspecific
binding was blocked by incubation with block and sample buffer
(Promega) for 1 h at room temperature. Plates were then washed,
and 100 ml sample supernatants were added. Plates were then
sealed and incubated for 6 h at room temperature. Plates were
then washed, polyclonal anti-human GDNF in block and sample
buffer was added, and plates were incubated overnight at 4uC.
After incubation, plates were washed and then incubated with
anti-IGY HRP-conjugated secondary antibody in block and
sample buffer for 1 h at room temperature. Plates were then
washed, and TMB One solution (Promega) was added to each well
for 10 min. The color change reaction was then terminated by
addition of 1 N hydrochloric acid, and absorbance was measured
at 450 nm using a plate reader.
Detection of p-ERK1/2 and p-Akt in pure neuronal
cultures
Cultured striatal neurons were starved from serum and kept in
MS for 24 h; afterwards, they were exposed to LY379268 (1 mM)
for 15 min, in the presence or absence of LY341495 (1 mM) at
37uC. Neuronal cells were washed twice with PBS and lysed in
Triton X-100 lysis buffer (containing: Tris-HCl, 50 mM, pH 7.5;
Triton X-100, 1%; NaCl, 100 mM; EDTA, 5 mM; NaF, 50 mM;
b-glycerophosphate, 40 mM; sodium ortovanadate, 200 mM;
PMSF, 100 mM; leupeptin, 1 mg/ml; pepstatin A, 1 mg/ml) for
15 min at 4uC. Samples were centrifuged at 12,000 g for 10 min
at 4uC. Equal amounts of proteins (100 mg) from supernatants
were separated by 12.5% (p-ERK1/2) or 7.5% (p-Akt) SDS-
polyacrylamide gel. After separation, proteins were transferred on
nitrocellulose membranes. Membranes were incubated with an
antibody against phosphorylated extracellular signal regulated
kinase, ERK1/2 (phospho-p44/42 MAPK monoclonal antibody,
1:2000; New England Biolabs, Beverly, MA, USA) for 2 h at room
temperature or with an antibody against phosphorylated Akt
(1:1000, rabbit polyclonal phospho-Akt (Ser473) antibody; New
England Biolabs) overnight at 4uC. Blots were then incubated for
1 h with the secondary antibody (1:5000, peroxidase-coupled anti-
mouse or 1:8000, peroxidase-coupled anti-rabbit; Amersham).
Immunostaining was revealed by the enhanced ECL western
blotting analysis system (Amersham). The same blots were
normalized against anti-ERK1/2 or anti-Akt antibodies (1:1000;
New England Biolabs).
Tyrosine hydroxylase (TH), glial cell line-derived
neurotrophic factor (GDNF) and glial fibrillary acidic
protein (GFAP) immunostaining
Brains were dissected out and immediately placed in a solution
composed of ethyl alcohol (60%), acetic acid (10%) and
chloroform (30%). Twenty h later brains were placed in 70%
ethanol until they were included in paraffin. Ten mm serial sections
were cut and used for histological analysis. Tissue sections were
incubated over-night with monoclonal mouse antibody (1:200;
Sigma, St. Louis, MO), or with polyclonal rabbit antibody (1:20;
Santa Cruz Biotechnology, Tebu, France) or monoclonal mouse
antibody (1:400 Sigma, St. Louis, MO), for the detection of TH,
GDNF and GFAP, respectively, and then for 1 h with secondary
mGlu3 Receptors and GDNF
PLoS ONE | www.plosone.org 12 August 2009 | Volume 4 | Issue 8 | e6591biotin coupled anti-mouse and anti-rabbit (1:200 Vector labora-
tories, Burlingame, CA) antibodies for the detection of TH, and
fluorescein isothiocyanate-conjugated horse anti-mouse IgG
(1:100; Vector laboratories, Burlingame, CA) for the detection of
GDNF and GFAP. Control staining was performed without the
primary antibodies.
Stereological cell counts of TH-positive cells in the
substantia nigra pars compacta
The number of TH-positive cells in the pars compacta of the
substantia nigra was obtained by stereological technique and the
optical fractionator, using a a Zeiss Axio Imager.M1 microscope
equipped with a motorized stage and focus control system (Zeta
axis) and a digital video camera. The software Image-Pro Plus
Windows 6.2 (Media Cybernetics, Inc., Bethesda, MD) was used
to control the microscope and to analyze digital images. The
analysis was performed on ten sections (10 mm) sampled every
150 mm in a rostro-caudal extension. In each stained section, the
area was identified and outlined (magnification of 2.56). Within
each delineated region, neurons were counted (magnification of
1006) according to the optical dissector method counting several
boxes (250 mm
262 mm) [58,59,60,61]. The total number of TH-
immunoreactive neurons per each rostro-caudal level was
computed from the formula: N=S(n)61/SSF61/ASF61/TSF)
where n is the total number of neurons counted on each dissector,
SSF (fraction of sections sampled) is the number of regularly
spaced sections used for counts divided by the total number of
sections through the substantia nigra pars compacta (=1/15); ASF
(area sampling frequency) is the dissector area divided by the area
between dissectors (=(2500 mm
26dissectors number)/region area)
and TSF (thickness sampling frequency) is the dissector thickness
divided by the section thickness (=2 mm/10 mm). The total
number of TH-immunoreactive neurons in the substantia
nigra pars compacta is the sum of the total number of TH-
immunoreactive neurons per each rostro-caudal level:
Ntot=S(Ni).
Quantitative evaluation and statistical analysis
In the in situ hybridization study the semiquantitative data of
mRNA levels were obtained by measuring the optical density
(O.D.) values of the labelling in the film autoradiograms on a
personal computer using Image J software. The values for the
region measured were defined as those obtained by subtracting the
non specific background values. For each experimental group the
O.D. values or silver grain counts represent the average of
readings from brain sections of four mice. For each experimental
condition two independent experiments were performed. The data
from in situ hybridization or Western blotting were evaluated by
one-way ANOVA with intergroup differences analysed by Fisher’s
Protected Last Significant Difference PLSD test, corrected by
Bonferoni’s procedure for dependent samples.
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